Free radicals and antioxidants: How to reestablish redox homeostasis in chronic diseases?

Current Medicinal Chemistry

Volumn 20, Issue 27, 2013, Pages 3397-3415

  Bocci, V ^a   Valacchi, G ^b,c  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c Kyung Hee University   (South Korea)

Author keywords

Antioxidants; Caloric restriction; Chronic oxidative stress; Exercise stress; Ozonetherapy; Reactive oxygen species; Redox regulation

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CURCUMIN; CYTOCHROME; FREE RADICAL; GENISTEIN; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTATHIONE DISULFIDE; ISOPROSTANE DERIVATIVE; NEUROTRANSMITTER; NITRIC OXIDE SYNTHASE; NORPHENAZONE; OXIDOREDUCTASE; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RESVERATROL; SINGLET OXYGEN; SULFORAPHANE; SUPEROXIDE DISMUTASE;

AGING; ALZHEIMER DISEASE; ATHEROSCLEROSIS; CALORIC RESTRICTION; CELL STRESS; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DOWN SYNDROME; DRUG EFFICACY; GENETIC ASSOCIATION; HEART INFARCTION; HOMEOSTASIS; HUMAN; MULTIPLE SCLEROSIS; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; OXYGEN CONCENTRATION; PARKINSON DISEASE; PULMONARY HYPERTENSION; REGULATORY MECHANISM; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; SMOOTH MUSCLE RELAXATION; THROMBOCYTE ADHESION;

EID: 84883271387     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320270005     Document Type: Review

References (304)

1. Harman, D. Aging: a theory based on free radical and radiation chemistry. J. Gerontol., 1956, 11, 298-300.
2. Harman, D. Nutritional implications of the free-radical theory of aging. J. Am. Coll. Nutr., 1982, 1, 27-34.
3. Harman, D. The aging process: major risk factor for disease and death. Proc. Natl. Acad. Sci. U S A., 1991, 88, 5360.
4. McCord, J. M.; Fridovich, I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J. Biol. Chem., 1969, 244, 6049-6055.
5. Dröge, W. Free radicals in the physiological control of cell function. Physiol. Rev., 2002, 82, 47-95.
6. Graves, D. B. The emerging role of reactive oxygen and nitrogen species in redox biology and some implications for plasma applications to medicine and biology. J. Phys. D: Appl. Phys., 2012, 45, 1-92.
7. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M. T.; Mazur, M.; Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol., 2007, 39, 44-84.
8. Bartz, R. R.; Piantadosi, C. A. Clinical review: oxygen as a signaling molecule. Crit. Care, 2010, 14, 234-242.
9. Circu, M. L.; Aw, T. Y. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic. Biol. Med., 2010, 48, 749-762.
10. Ray, P. D.; Huang, B. W.; Tsuji, Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal., 2012, 24, 981-990.
11. Segal, B. H.; Grimm, M. J.; Khan, A. N.; Han, W.; Blackwell, T. S. Regulation of innate immunity by NADPH oxidase. Free Radic. Biol. Med., 2012, 53, 72-80.
12. Cadenas, E.; Davies, K. J. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic. Biol. Med., 2000, 29, 222-230.
13. Groeger, G.; Quiney, C.; Cotter, T. G. Hydrogen peroxide as a cellsurvival signalling molecule. Antioxid. Redox. Signal., 2009, 11, 2655-2671.
14. Ayer, A.; Tan, S. X.; Grant, C. M.; Meyer, A. J.; Dawes, I. W.; Perrone, G. G. The critical role of glutathione in maintenance of the mitochondrial genome. Free Radic. Biol. Med., 2010, 49, 1956-1968.
15. Pastore, A.; Federici, G.; Bertini, E; Piemonte, F. Analysis of glutathione: implication in redox and detoxification. Clin. Chim. Acta., 2003, 333, 19-39.
16. Sagara, Y.; Dargusch, R.; Chambers, D.; Davis, J.; Schubert, D.; Maher, P. Cellular mechanisms of resistance to chronic oxidative stress. Free Radic. Biol. Med., 1998, 24, 1375-1389.
17. Bergendi, L.; Benes, L.; Duracková, Z.; Ferencik, M. Chemistry, physiology and pathology of free radicals. Life Sci., 1999, 65, 1865-1874.
18. Jones, D. P.; Carlson, J. L.; Mody, V. C.; Cai, J.; Lynn, M. J.; Sternberg, P. Redox state of glutathione in human plasma. Free Radic. Biol. Med., 2000, 28, 625-635.
19. Nogueira, C. W.; Zeni, G.; Rocha, J. B. Organoselenium and organotellurium compounds: toxicology and pharmacology. Chem. Rev., 2004, 104, 6255-6285.
20. Shen, D.; Dalton, T. P.; Nebert, D. W.; Shertzer, H. G. Glutathione redox state regulates mitochondrial reactive oxygen production. J. Biol. Chem., 2005, 280, 25305-25312.
21. Packer, L.; Cadenas, E. Lipoic acid: energy metabolism and redox regulation of transcription and cell signaling. J. Clin. Biochem. Nutr., 2011, 48, 26-32.
22. Rhee, S. G.; Chae, H. Z.; Kim, K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic. Biol. Med., 2005, 38, 1543-1552.
23. Kemp, M.; Go, Y. M.; Jones, D. P. Nonequilibrium thermodynamics of thiol/disulfide redox systems: a perspective on redox systems biology. Free Radic. Biol. Med., 2008, 44, 921-937.
24. Cardoso, A. R.; Chausse, B.; da Cunha, F. M.; Luévano- Martínez, L. A.; Marazzi, T. B.; Pessoa, P. S.; Queliconi, B. B.; Kowaltowski, A. J. Mitochondrial compartmentalization of redox processes. Free Radic. Biol. Med., 2012, 52, 2201-2208.
25. Andreyev, A. Y.; Kushnareva, Y. E.; Starkov, A. A. Mitochondrial metabolism of reactive oxygen species. Biochemistry (Mosc)., 2005, 70, 200-214.
26. Chatterjee, A.; Black, S. M.; Catravas, J. D. Endothelial nitric oxide (NO) and its pathophysiologic regulation. Vascul. Pharmacol., 2008, 49, 134-140.
27. Gow, A. J.; Stamler, J. S. Reactions between nitric oxide and haemoglobin under physiological conditions. Nature, 1998, 391, 169-173.
28. Stamler, J. S. Redox signaling: nitrosylation and related target interactions of nitric oxide. Cell, 1994, 78, 931-936.
29. Tong, L.; Heim, R. A.; Wu, S. Nitric oxide: a regulator of eukaryotic initiation factor 2 kinases. Free Radic. Biol. Med., 2011, 50, 1717-1725.
30. Lubos, E.; Handy, D. E.; Loscalzo, J. Role of oxidative stress and nitric oxide in atherothrombosis. Front. Biosci., 2008, 13, 5323-5344.
31. Zhang, Y.; Hogg, N. S-Nitrosothiols: cellular formation and transport. Free Radic. Biol. Med., 2005, 38, 831-838.
32. Sies, H. Strategies of antioxidant defense. Eur. J. Biochem., 1993, 215, 213-219.
33. Winyard, P. G.; Moody, C. J.; Jacob, C. Oxidative activation of antioxidant defence. Trends Biochem. Sci., 2005, 30, 453-461.
34. Bylund, J.; Brown, K. L.; Movitz, C.; Dahlgren, C.; Karlsson, A. Intracellular generation of superoxide by the phagocyte NADPH oxidase: how, where, and what for? Free Radic. Biol. Med., 2010, 49, 1834-1845.
35. Kelley, E. E.; Khoo, N. K.; Hundley, N. J.; Malik, U. Z.; Freeman, B. A.; Tarpey, M. M. Hydrogen peroxide is the major oxidant product of xanthine oxidase. Free Radic. Biol. Med., 2010, 48, 493-498.
36. Nathan, C. F.; Root, R. K. Hydrogen peroxide release from mouse peritoneal macrophages: dependence on sequential activation and triggering. J. Exp. Med., 1977, 146, 1648-1662.
37. Lambeth, J. D. NOX enzymes and the biology of reactive oxygen. Nat. Rev. Immunol., 2004, 4, 181-189.
38. Feng, L.; Xia, Y.; Garcia, G. E.; Hwang, D.; Wilson, C. B. Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha, and lipopolysaccharide. J. Clin. Invest., 1995, 95, 1669-1675.
39. Korsmeyer, S. J. Regulators of cell death. Trends Genet., 1995, 11, 101-105.
40. Slater, A. F.; Stefan, C.; Nobel, I.; van den Dobbelsteen, D. J.; Orrenius, S. Signalling mechanisms and oxidative stress in apoptosis. Toxicol. Lett., 1995, 82-83, 149-153.
41. Um, H. D.; Orenstein, J. M.; Wahl, S. M. Fas mediates apoptosis in human monocytes by a reactive oxygen intermediate dependent pathway. J. Immunol., 1996, 156, 3469-347.
42. Morgan, M. J.; Kim, Y. S.; Liu, Z. G. TNFalpha and reactive oxygen species in necrotic cell death. Cell Res., 2008, 18, 343-349.
43. Kim, K. M.; Kim, P. K.; Kwon, Y. G.; Bai, S. K.; Nam, W. D.; Kim, Y. M. Regulation of apoptosis by nitrosative stress. J. Biochem. Mol. Biol., 2002, 35, 127-133.
44. Niki, E. Lipid peroxidation: physiological levels and dual biological effects. Free Radic. Biol. Med., 2009, 47, 469-484.
45. Luo, Y.; Roth, G. S. The roles of dopamine oxidative stress and dopamine receptor signaling in aging and age-related neurodegeneration. Antioxid. Redox. Signal., 2000, 2, 449-460.
46. Pryor, W. A. Oxy-radicals and related species: their formation, lifetimes, and reactions. Annu. Rev. Physiol., 1986, 48, 657-667.
47. Roche, M.; Rondeau, P.; Singh, N. R.; Tarnus, E.; Bourdon, E. The antioxidant properties of serum albumin. FEBS Lett., 2008, 582, 1783-1787.
48. Ogino, K.; Wang, D. H. Biomarkers of oxidative/nitrosative stress: an approach to disease prevention. Acta Med. Okayama., 2007, 61, 181-189.
49. Tsukahara, H. Biomarkers for oxidative stress: clinical application in pediatric medicine. Curr. Med. Chem., 2007, 14, 339-351.
50. Dalle-Donne, I.; Rossi, R.; Colombo, R.; Giustarini, D.; Milzani, A. Biomarkers of oxidative damage in human disease. Clin. Chem., 2006, 52, 601-623.
51. Dalle-Donne, I.; Rossi, R.; Giustarini, D.; Colombo, R.; Milzani, A. S-glutathionylation in protein redox regulation. Free Radic. Biol. Med., 2007, 43, 883-898.
52. Valavanidis, A.; Vlachogianni, T.; Fiotakis, C. 8-hydroxy-2′- deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. J. Environ. Sci. Health C. Environ. Carcinog. Ecotoxicol. Rev., 2009, 27, 120-139.
53. Nakamura, Y.; Yasuoka, H.; Tsujimoto, M.; Yoshidome, K.; Nakahara, M.; Nakao, K.; Nakamura, M.; Kakudo, K. Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. Clin. Cancer Res., 2006, 12, 1201-1207.
54. Bentz, B. G.; Haines, G. K. 3rd; Radosevich, J. A. Increased protein nitrosylation in head and neck squamous cell carcinogenesis. Head Neck, 2000, 22, 64-70.
55. Ekmekcioglu, S.; Ellerhorst, J.; Smid, C. M.; Prieto, V. G.; Munsell, M.; Buzaid, A. C.; Grimm, E. A. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin. Cancer Res., 2000, 6, 4768-4775.
56. Karihtala, P.; Kauppila, S.; Puistola, U.; Jukkola-Vuorinen, A. Divergent behaviour of oxidative stress markers 8-hydroxydeoxyguanosine (8-OHdG) and 4-hydroxy-2-nonenal (HNE) in breast carcinogenesis. Histopathology, 2011, 58, 854-862.
57. Young, O.; Crotty, T.; O'Connell, R.; O'Sullivan, J.; Curran, A. J. Levels of oxidative damage and lipid peroxidation in thyroid neoplasia. Head Neck, 2010, 32, 750-756.
58. Skrzydlewska, E.; Sulkowski, S.; Koda, M.; Zalewski, B.; Kanczuga-Koda, L.; Sulkowska, M. Lipid peroxidation and antioxidant status in colorectal cancer. World J. Gastroenterol., 2005, 11, 403-406.
59. Reuter, S.; Gupta, S. C.; Chaturvedi, M. M.; Aggarwal, B. B. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic. Biol. Med., 2010, 49, 1603-1616.
60. Méndez, J. D.; Xie, J.; Aguilar-Hernández, M.; Méndez-Valenzuela, V. Trends in advanced glycation end products research in diabetes mellitus and its complications. Mol. Cell. Biochem., 2010, 341, 33-41.
61. Bir, S. C.; Kevil, C. G. Diabetic neutrophil mitochondrial dysfunction: an inflammatory situation? Free Radic. Biol. Med., 2011, 50, 1213-1214.
62. Huijberts, M. S.; Schaper, N. C.; Schalkwijk, C. G. Advanced glycation end products and diabetic foot disease. Diabetes Metab. Res. Rev., 2008, 24, S19-S24.
63. Ling, X.; Nagai, R.; Sakashita, N.; Takeya, M.; Horiuchi, S.; Takahashi, K. Immunohistochemical distribution and quantitative biochemical detection of advanced glycation end products in fetal to adult rats and in rats with streptozotocin-induced diabetes. Lab. Invest., 2001, 81, 845-861.
64. Giacco, F.; Brownlee, M. Oxidative stress and diabetic complications. Circ. Res., 2010, 107, 1058-1070.
65. Pijpers, E. Morbidity and mortality risk of aging diabetic and psychogeriatric patients. PhD thesis, Maastricht University: Maastricht, May 2012.
66. Ahima, R. S. Connecting obesity, aging and diabetes. Nat. Med., 2009, 15, 996-997.
67. Minamino, T.; Orimo, M.; Shimizu, I.; Kunieda, T.; Yokoyama, M.; Ito, T.; Nojima, A.; Nabetani, A.; Oike, Y.; Matsubara, H.; Ishikawa, F.; Komuro, I. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat. Med., 2009, 15, 1082-1087.
68. Tsutsui, H.; Kinugawa, S.; Matsushima, S. Oxidative stress and heart failure. Am. J. Physiol. Heart Circ. Physiol., 2011, 301, H2181-H2190.
69. Granger, D. N. Role of xanthine oxidase and granulocytes in ischemia-reperfusion injury. Am. J. Physiol., 1988, 255, H1269-H1275.
70. Karin, M.; Liu, Z.; Zandi, E. AP-1 function and regulation. Curr. Opin. Cell Biol., 1997, 9, 240-246.
71. Schreck, R.; Rieber, P.; Baeuerle, P. A. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J., 1991, 10, 2247-2258.
72. Li, J. M.; Shah, A. M. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2004, 287, R1014-R1030.
73. De Keulenaer, G. W.; Alexander, R. W.; Ushio-Fukai, M.; Ishizaka, N.; Griendling, K. K. Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. Biochem. J., 1998, 329, 653-657.
74. Mohazzab, K. M.; Kaminski, P. M.; Wolin, M. S. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am. J. Physiol., 1994, 266, H2568-H2572.
75. Ohara, Y.; Peterson, T. E.; Harrison, D. G. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest., 1993, 91, 2546-2551.
76. Aronow, W. S. Current approaches to the treatment of hypertension in older persons. Postgrad. Med., 2012, 124, 50-59.
77. Basu, S.; Whiteman, M.; Mattey, D.L.; Halliwell, B. Raised levels of F (2)-isoprostanes and prostaglandin F(2alpha) in different rheumatic diseases. Ann. Rheum. Dis., 2001, 60, 627-631.
78. Mäki-Petäjä, K. M.; Elkhawad, M.; Cheriyan, J.; Joshi, F. R.; Ostör, A. J.; Hall, F. C.; Rudd, J. H.; Wilkinson, I. B. Anti-Tumor Necrosis Factor-αTherapy Reduces Aortic Inflammation and Stiffness in Patients With Rheumatoid Arthritis. Circulation, 2012, 126, 2473-2480.
79. Mapp, P. I.; Grootveld M. C.; Blake D. R. Hypoxia, oxidative stress and rheumatoid arthritis. Br. Med. Bull., 1995, 51, 419-436.
80. Hoshikawa, Y.; Ono, S.; Suzuki, S.; Tanita, T.; Chida, M.; Song, C.; Noda, M.; Tabata, T.; Voelkel, N. F.; Fujimura, S. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J. Appl. Physiol., 2001, 90, 1299-1306.
81. Rabinovitch, M. Molecular pathogenesis of pulmonary arterial hypertension. J. Clin. Invest., 2008, 118, 2372-2379.
82. Tabima, D. M.; Frizzell, S.; Gladwin, M. T. Reactive oxygen and nitrogen species in pulmonary hypertension. Free Radic. Biol. Med., 2012, 52, 1970-1986.
83. Papaiahgari, S.; Kleeberger, S. R.; Cho, H. Y.; Kalvakolanu, D. V.; Reddy, S. P. NADPH oxidase and ERK signaling regulates hyperoxia-induced Nrf2-ARE transcriptional response in pulmonary epithelial cells. J. Biol. Chem., 2004, 279, 42302-42312.
84. Barnes, P. J. Chronic obstructive pulmonary disease. N. Engl. J. Med., 2000, 343, 269-280.
85. DeMarini, D. M. Genotoxicity of tobacco smoke and tobacco smoke condensate: a review. Mutat. Res., 2004, 567, 447-474.
86. Rangasamy, T.; Cho, C. Y.; Thimmulappa, R. K.; Zhen, L.; Srisuma, S. S.; Kensler, T. W.; Yamamoto, M.; Petrache, I.; Tuder, R. M.; Biswal, S. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J. Clin. Invest., 2004, 114, 1248-1259.
87. Jaspers, I.; Flescher, E.; Chen, L. C. Respiratory epithelial cells display polarity in their release of the chemokine IL-8 after exposure toozone. Inflamm. Res., 1997, 46, S173-s174.
88. Mannino, D. M.; Kiriz, V. A. Changing the burden of COPD mortality. Int. J. Chron. Obstruct. Pulmon. Dis., 2006, 1, 219-233.
89. Pagano, G.; Castello, G. Oxidative stress and mitochondrial dysfunction in Down syndrome. Adv. Exp. Med. Biol., 2012, 724, 291-299.
90. van Horssen. J.; Witte, M. E.; Schreibelt, G.; de Vries, H. E. Radical changes in multiple sclerosis pathogenesis. Biochim. Biophys. Acta., 2011, 1812, 141-150.
91. Floyd, R. A.; Hensley, K. Oxidative stress in braing aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol. Aging., 2002, 23, 795-807.
92. Jomova, K.; Vondrakova, D.; Lawson, M.; Valko, M. Metals, oxidative stress and neurodegenerative disorders. Mol. Cell. Biochem., 2010, 345, 91-104.
93. Bradley, M. A.; Markesbery, W. R.; Lovell, M. A. Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease. Free Radic. Biol. Med., 2010, 48, 1570-1576.
94. Seet, R. C.; Lee, C. Y.; Lim, E. C.; Tan, J. J.; Quek, A. M.; Chong, W. L.; Looi, W. F.; Huang, S. H.; Wang, H.; Chan, Y. H.; Halliwell, B. Oxidative damage in Parkinson disease: Measurement using accurate biomarkers. Free Radic. Biol. Med., 2010, 48, 560-566.
95. Epping-Jordan, J. E.; Galea, G.; Tukuitonga, C.; Beaglehole, R. Preventing chronic diseases: taking stepwise action. Lancet, 2005, 366, 1667-1671.
96. Reynolds, K.; He, J. Epidemiology of the metabolic syndrome. Am J Med Sci., 2005, 330, 273-279.
97. Halliwell, B. The antioxidant paradox. Lancet, 2000, 355, 1179-1180.
98. Halliwell, B.; Rafter, J.; Jenner, A. Health promotion by flavonoids, tocopherols, tocotrienols, and other phenols: direct or indirect effects? Antioxidant or not? Am. J. Clin. Nutr., 2005, 81, 268S-276S.
99. Halliwell, B. Dietary polyphenols: good, bad, or indifferent for your health? Cardiovasc Res., 2007, 73, 341-347.
100. Halliwell, B. Flavonoids: a re-run of the carotenoids story? Novartis Found Symp., 2007, 282, 93-101.
101. Halliwell, B. Free radicals and antioxidants-quo vadis? Trends Pharmacol. Sci., 2011, 32, 125-130.
102. Bader, N.; Bosy-Westphal, A.; Koch, A.; Mueller, M. J. Influence of vitamin C and E supplementation on oxidative stress induced by hyperbaric oxygen in healthy men. Ann. Nutr. Metab., 2006, 50, 173-176.
103. Bishayee, A.; Politis, T.; Darvesh, A. S. Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat. Rev., 2010, 36, 43-53.
104. Cochemé, H. M.; Murphy, M. P. Can antioxidants be effective therapeutics? Curr. Opin. Investig. Drugs., 2010, 11, 426-431.
105. Engelhart, M. J.; Geerlings, M. I.; Ruitenberg, A.; van Swieten, J. C.; Hofman, A.; Witteman, J. C.; Breteler, M. M. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA., 2002, 287, 3223-3229.
106. Evans, J. R.; Henshaw, K. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane. Database Syst. Rev., 2008, (1), CD000253.
107. Goodman, M.; Bostick, R. M.; Kucuk, O.; Jones, D. P. Clinical trials of antioxidants as cancer prevention agents: past, present, and future. Free Radic. Biol. Med., 2011, 51, 1068-1084.
108. Hertog, M. G.; Feskens, E. J.; Hollman, P. C.; Katan, M. B.; Kromhout, D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet, 1993, 342, 1007-1011.
109. Hill, M. F. Emerging role for antioxidant therapy in protection against diabetic cardiac complications: experimental and clinical evidence for utilization of classic and new antioxidants. Curr. Cardiol. Rev., 2008, 4, 259-268.
110. Iannitti, T.; Palmieri, B. Antioxidant therapy effectiveness: an up to date. Eur. Rev. Med. Pharmacol. Sci., 2009, 13, 245-278.
111. Lirussi, F.; Azzalini, L.; Orando, S.; Orlando, R.; Angelico, F. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst. Rev., 2007, (1), CD004996.
112. Mirshafiey, A.; Mohsenzadegan, M. Antioxidant therapy in multiple sclerosis. Immunopharmacol. Immunotoxicol., 2009, 31, 13-29.
113. Oter, S.; Jin, S.; Cucullo, L.; Dorman, H. J. D. Oxidants and antioxidants: friends or foes? Oxid. Antioxid. Med. Sci., 2012, 1, 1-4.
114. Schafer, F. Q.; Buettner, G. R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic. Biol. Med., 2001, 30, 1191-212.
115. Singh, U.; Jialal, I. Alpha-lipoic acid supplementation and diabetes. Nutr. Rev., 2008, 66, 646-657.
116. Firuzi, O.; Miri, R.; Tavakkoli, M.; Saso, L. Antioxidant therapy: current status and future prospects. Curr. Med. Chem., 2011, 18, 3871-3888.
117. Watanabe, T.; Tahara, M.; Todo, S. The novel antioxidant edaravone: from bench to bedside. Cardiovasc. Ther., 2008, 26, 101-114.
118. Yoshida, H.; Yanai, H.; Namiki, Y.; Fukatsu-Sasaki, K.; Furutani, N.; Tada, N. Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury. CNS Drug Rev., 2006, 12, 9-20.
119. Hishida, A. Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance. Clin. Exp. Nephrol., 2007, 11, 292-296.
120. Aldini, G.; Gamberoni, L.; Orioli, M.; Beretta, G.; Regazzoni, L.; Maffei Facino, R.; Carini, M. Mass spectrometric characterization of covalent modification of human serum albumin by 4-hydroxytrans-2-nonenal. J. Mass Spectrom., 2006, 41, 1149-1161.
121. Aldini, G.; Vistoli, G.; Regazzoni, L.; Gamberoni, L.; Facino, R. M.; Yamaguchi, S.; Uchida, K.; Carini, M. Albumin is the main nucleophilic target of human plasma: a protective role against proatherogenic electrophilic reactive carbonyl species? Chem. Res. Toxicol., 2008, 21, 824-835.
122. Rice-Evans, C.; Miller, N. J. Total antioxidant status in plasma and body fluids. Methods Enzymol., 1994, 234, 279-293.
123. Elmedal, B.; de Dam, M. Y.; Mulvany, M. J.; Simonsen, U. The superoxide dismutase mimetic, tempol, blunts right ventricular hypertrophy in chronic hypoxic rats. Br. J. Pharmacol., 2004, 141, 105-113.
124. Ristow, M.; Zarse, K.; Oberbach, A.; Klöting, N.; Birringer, M.; Kiehntopf, M.; Stumvoll, M.; Kahn, C. R.; Blüher, M. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc. Natl. Acad. Sci. U S A., 2009, 106, 8665-8670.
125. Aggarwal, B. B.; Harikumar, K. B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol., 2009, 41, 40-59.
126. Goel, A.; Kunnumakkara, A. B.; Aggarwal, B. B. Curcumin as "Curecumin": from kitchen to clinic. Biochem. Pharmacol., 2008, 75, 787-809.
127. Gupta, S. C.; Patchva, S.; Koh, W.; Aggarwal, B. B. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin. Exp. Pharmacol. Physiol., 2012, 39, 283-299.
128. Kim, J. H.; Gupta, S. C.; Park, B.; Yadav, V. R.; Aggarwal, B. B. Turmeric (Curcuma longa) inhibits inflammatory nuclear factor (NF)-κB and NF-κB-regulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesis. Mol. Nutr. Food Res., 2012, 56, 454-465.
129. Lim, K. J.; Bisht, S.; Bar, E. E.; Maitra, A.; Eberhart, C. G. A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol. Ther., 2011, 11, 464-473.
130. Agarwal, B.; Baur, J. A. Resveratrol and life extension. Ann. N. Y. Acad. Sci., 2011, 1215, 138-143.
131. Barger, J. L.; Kayo, T.; Vann, J. M.; Arias, E. B.; Wang, J.; Hacker, T. A.; Wang, Y.; Raederstorff, D.; Morrow, J. D.; Leeuwenburgh, C.; Allison, D. B.; Saupe, K. W.; Cartee, G. D.; Weindruch, R.; Prolla, T. A. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One., 2008, 3, e2264.
132. Barger, J. L.; Kayo, T.; Pugh, T. D.; Prolla, T. A.; Weindruch, R. Short-term consumption of a resveratrol-containing nutraceutical mixture mimics gene expression of long-term caloric restriction in mouse heart. Exp. Gerontol., 2008, 43, 859-866.
133. Baur, J. A.; Pearson, K. J.; Price, N. L.; Jamieson, H. A.; Lerin, C.; Kalra, A.; Prabhu, V. V.; Allard, J. S.; Lopez-Lluch, G.; Lewis, K.; Pistell, P. J.; Poosala, S.; Becker, K. G.; Boss, O.; Gwinn, D.; Wang, M.; Ramaswamy, S.; Fishbein, K. W.; Spencer, R. G.; Lakatta, E. G.; Le Couteur, D.; Shaw, R. J.; Navas, P.; Puigserver, P.; Ingram, D. K.; de Cabo, R.; Sinclair, D. A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 2006, 444, 337-342.
134. Baur, J. A.; Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov., 2006, 5, 493-506.
135. Chung, J. H.; Manganiello, V.; Dyck, J. R. Resveratrol as a calorie restriction mimetic: therapeutic implications. Trends Cell. Biol., 2012, 22, 546-554.
136. Jang, M.; Cai, L.; Udeani, G. O.; Slowing, K. V.; Thomas, C. F.; Beecher, C. W.; Fong, H. H.; Farnsworth NR.; Kinghorn AD.; Mehta RG.; Moon RC.; Pezzuto JM. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 1997, 275, 218-220.
137. Milne, J. C.; Lambert, P. D.; Schenk, S.; Carney, D. P.; Smith, J. J.; Gagne, D. J.; Jin, L.; Boss, O.; Perni, R. B.; Vu, C. B.; Bemis, J. E.; Xie, R.; Disch, J. S.; Ng, P. Y.; Nunes, J. J.; Lynch, A. V.; Yang, H.; Galonek, H.; Israelian, K.; Choy, W.; Iffland, A.; Lavu, S.; Medvedik, O.; Sinclair, D. A.; Olefsky, J. M.; Jirousek, M. R.; Elliott, P. J.; Westphal, C. H. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature, 2007, 450, 712-716.
138. Subramanian, L.; Youssef, S.; Bhattacharya, S.; Kenealey, J.; Polans, A. S.; van Ginkel, P. R. Resveratrol: challenges in translation to the clinic - a critical discussion. Clin. Cancer Res., 2010, 16, 5942-5948.
139. Bordone, L.; Guarente, L. Calorie restriction, SIRT1 and metabolism: understanding longevity. Nat. Rev. Mol. Cell Biol., 2005, 6, 298-305.
140. Imai, S. A possibility of nutriceuticals as an anti-aging intervention: activation of sirtuins by promoting mammalian NAD biosynthesis. Pharmacol. Res., 2010, 62, 42-47.
141. Leibiger, I. B.; Berggren, P. O. Sirt1: a metabolic master switch that modulates lifespan. Nat. Med., 2006, 12, 34-36.
142. Smith, B. C.; Hallows, W. C.; Denu, J. M. Mechanisms and molecular probes of sirtuins. Chem. Biol., 2008, 15, 1002-1013.
143. Fahey, J. W.; Zhang, Y.; Talalay, P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc. Natl. Acad. Sci. U S A., 1997, 94, 10367-10372.
144. Fahey, J. W.; Haristoy, X.; Dolan, P. M.; Kensler, T. W.; Scholtus, I.; Stephenson, K. K.; Talalay, P.; Lozniewski, A. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc. Natl. Acad. Sci. U S A., 2002, 99, 7610-7615.
145. Finley, J. W.; Sigrid-Keck, A.; Robbins, R. J.; Hintze, K. J. Selenium enrichment of broccoli: interactions between selenium and secondary plant compounds. J. Nutr., 2005, 135, 1236-1238.
146. Agyeman, A. S.; Chaerkady, R.; Shaw, P. G.; Davidson, N. E.; Visvanathan, K.; Pandey, A.; Kensler, T. W. Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles. Breast Cancer Res. Treat., 2012, 132, 175-187.
147. Meeran, S. M.; Patel, S. N.; Tollefsbol, T. O. Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS One., 2010, 5, e11457.
148. Pabona, J. M.; Dave, B.; Su, Y.; Montales, M. T.; de Lumen, B. O.; de Mejia, E. G.; Rahal, O. M.; Simmen, R. C. The soybean peptide lunasin promotes apoptosis of mammary epithelial cells via induction of tumor suppressor PTEN: similarities and distinct actions from soy isoflavone genistein. Genes. Nutr., 2013, 8, 79-90.
149. Ahmed, S.; Pakozdi, A.; Koch, A. E. Regulation of interleukin-1beta- induced chemokine production and matrix metalloproteinase 2 activation by epigallocatechin-3-gallate in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum., 2006, 54, 2393-2401.
150. Ahmed, S.; Marotte, H.; Kwan, K.; Ruth, J. H.; Campbell, P. L.; Rabquer, B. J.; Pakozdi, A.; Koch, A. E. Epigallocatechin-3-gallate inhibits IL-6 synthesis and suppresses transsignaling by enhancing soluble gp130 production. Proc. Natl. Acad. Sci. U S A., 2008, 105, 14692-14697.
151. Litterio, M. C.; Jaggers, G.; Sagdicoglu Celep, G.; Adamo, A. M.; Costa, M. A.; Oteiza, P.,I.; Fraga, C. G.; Galleano, M. Blood pressure-lowering effect of dietary (-)-epicatechin administration in LNAME-treated rats is associated with restored nitric oxide levels. Free Radic. Biol. Med., 2012, 53, 1894-1902.
152. Pan, T.; Jankovic, J.; Le, W. Potential therapeutic properties of green tea polyphenols in Parkinson's disease. Drugs Aging., 2003, 20, 711-721.
153. Demedts, M.; Behr, J.; Buhl, R.; Costabel, U.; Dekhuijzen, R.; Jansen, H. M.; MacNee, W.; Thomeer, M.; Wallaert, B.; Laurent, F.; Nicholson, A. G.; Verbeken, E. K.; Verschakelen, J.; Flower, C. D.; Capron, F.; Petruzzelli, S.; De Vuyst, P.; van den Bosch, J. M.; Rodriguez-Becerra, E.; Corvasce, G.; Lankhorst, I.; Sardina, M.; Montanari, M; IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med., 2005, 353, 2229-2242.
154. Bocci, V. Può l'Ossigeno-Ozonoterapia migliorare la prognosi della bronco-pneumopatia cronica ostruttiva? Giorn. Ital. Mal. Tor., 2007, 61, 434-446.
155. Berk, M.; Copolov, D.; Dean, O.; Lu, K.; Jeavons, S.; Schapkaitz, I.; Anderson-Hunt, M.; Judd, F.; Katz, F.; Katz, P.; Ording-Jespersen, S.; Little, J.; Conus, P.; Cuenod, M.; Do, K. Q.; Bush, A. I. N-acetyl cysteine as a glutathione precursor for schizophrenia - a double-blind, randomized, placebo-controlled trial. Biol. Psychiatry, 2008, 64, 361-368.
156. Hartkorn, A.; Hoffmann, F.; Ajamieh, H.; Vogel, S.; Heilmann, J.; Gerbes, A. L.; Vollmar, A.M.; Zahler, S. Antioxidant effects of xanthohumol and functional impact on hepatic ischemiareperfusion injury. J. Nat. Prod., 2009, 72, 1741-1747.
157. Weindruch, R.; Walford, R. L. The retardation of aging and disease by dietary restriction. Charles C. Thomas Publisher: Springfield (Illinois), 1988.
158. Fontana, L.; Meyer, T. E.; Klein, S.; Holloszy, J. O. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc. Natl. Acad. Sci. U S A., 2004, 101, 6659-6663.
159. Fontana, L.; Villareal, D. T.; Weiss, E. P.; Racette, S. B.; Steger-May, K.; Klein, S.; Holloszy, J. O; and the Washington University School of Medicine CALERIE Group. Calorie restriction or exercise: effects on coronary heart disease risk factors. A randomized, controlled trial. Am. J. Physiol. Endocrinol. Metab., 2007, 293, E197-202.
160. Fontana, L. Calorie restriction and cardiometabolic health. Eur. J. Cardiovasc. Prev. Rehabil., 2008, 15, 3-9.
161. Fontana, L. The scientific basis of caloric restriction leading to longer life. Curr. Opin. Gastroenterol., 2009, 25, 144-150.
162. Heilbronn, L. K.; de Jonge, L.; Frisard, M. I.; DeLany, J. P.; Larson-Meyer, D. E.; Rood, J.; Nguyen, T.; Martin, C. K.; Volaufova, J.; Most, M. M.; Greenway, F. L.; Smith, S. R.; Deutsch, W. A.; Williamson, D. A.; Ravussin, E; Pennington CALERIE Team. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. JAMA., 2006, 295, 1539-1548.
163. Henry, R. R.; Scheaffer, L.; Olefsky, J. M. Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulindependent diabetes mellitus. J. Clin. Endocrinol. Metab., 1985, 61, 917-925.
164. Holloszy, J. O.; Fontana, L. Caloric restriction in humans. Exp. Gerontol., 2007, 42, 709-712.
165. Wadden, T. A.; Foster, G. D.; Letizia, K. A. One-year behavioral treatment of obesity: comparison of moderate and severe caloric restriction and the effects of weight maintenance therapy. J. Consult. Clin. Psychol., 1994, 62, 165-171.
166. Williams, K. V.; Mullen, M. L.; Kelley, D. E.; Wing, R. R. The effect of short periods of caloric restriction on weight loss and glycemic control in type 2 diabetes. Diabetes Care, 1998, 21, 2-8.
167. Colman, R. J.; Anderson, R. M.; Johnson, S. C.; Kastman, E. K.; Kosmatka, K. J.; Beasley, T. M.; Allison, D. B.; Cruzen, C.; Simmons, H. A.; Kemnitz, J. W.; Weindruch, R. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science, 2009, 325, 201-204.
168. Cruzen, C.; Colman, R. J. Effects of caloric restriction on cardiovascular aging in non-human primates and humans. Clin. Geriatr. Med., 2009, 25, 733-743, ix-x.
169. Shelton, L. M.; Huysentruyt, L. C.; Mukherjee, P.; Seyfried, T. N. Calorie restriction as an anti-invasive therapy for malignant brain cancer in the VM mouse. ASN Neuro., 2010, 2, e00038.
170. Li, Y.; Daniel, M.; Tollefsbol, T. O. Epigenetic regulation of caloric restriction in aging. BMC Med., 2011, 9, 98.
171. Nemoto, S.; Fergusson, M. M.; Finkel, T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science, 2004, 306, 2105-2108.
172. Cohen, H. Y.; Miller, C.; Bitterman, K. J.; Wall, N. R.; Hekking, B.; Kessler, B.; Howitz, K. T.; Gorospe, M.; de Cabo, R.; Sinclair, D. A. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science, 2004, 305, 390-392.
173. Rose, G.; Dato, S.; Altomare, K.; Bellizzi, D.; Garasto, S.; Greco, V.; Passarino, G.; Feraco, E.; Mari, V.; Barbi, C.; BonaFe, M.; Franceschi, C.; Tan, Q.; Boiko, S.; Yashin, A. I.; De Benedictis, G. Variability of the SIRT3 gene, human silent information regulator Sir2 homologue, and survivorship in the elderly. Exp. Gerontol., 2003, 38, 1065-1070.
174. Sack, M. N. The role of SIRT3 in mitochondrial homeostasis and cardiac adaptation to hypertrophy and aging. J. Mol. Cell Cardiol., 2012, 52, 520-525.
175. Sundaresan, N. R.; Samant, S. A.; Pillai, V. B.; Rajamohan, S. B.; Gupta, M. P. SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70. Mol. Cell. Biol., 2008, 28, 6384-6401.
176. Kanfi, Y.; Shalman R.; Peshti V.; Pilosof S. N.; Gozlan, Y. M.; Pearson, K. J.; Lerrer, B.; Moazed, D.; Marine, J. C.; de Cabo, R.; Cohen, H. Y.
177. Kanfi, Y.; Peshti, V.; Gil, R.; Naiman, S.; Nahum, L.; Levin, E.; Kronfeld-Schor, N.; Cohen, H. Y. SIRT6 protects against pathological damage caused by diet-induced obesity. Aging Cell., 2010, 9, 162-173.
178. Ciechanover, A.; Hod, Y.; Hershko, A. A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. 1978. Biochem. Biophys. Res. Commun., 2012, 425, 565-570.
179. Glickman, M. H.; Ciechanover, A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev., 2002, 82, 373-428.
180. Grune, T.; Davies, K. J. The proteasomal system and HNEmodified proteins. Mol. Aspects Med., 2003, 24, 195-204.
181. Chapple, S. J.; Siow, R. C.; Mann, G. E. Crosstalk between Nrf2 and the proteasome: therapeutic potential of Nrf2 inducers in vascular disease and aging. Int. J. Biochem. Cell. Biol., 2012, 44, 1315-1320.
182. Bader, N.; Grune, T. Protein oxidation and proteolysis. Biol. Chem., 2006, 387, 1351-1355.
183. Lehman, N. L. The ubiquitin proteasome system in neuropathology. Acta Neuropathol., 2009, 118, 329-347.
184. Olanow, C. W.; McNaught, K. S. Ubiquitin-proteasome system and Parkinson's disease. Mov. Disord., 2006, 21, 1806-1823.
185. Kwak, M. K.; Wakabayashi, N.; Greenlaw, J. L.; Yamamoto, M.; Kensler, T. W. Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway. Mol. Cell. Biol., 2003, 23, 8786-8794.
186. D'Arcy, P.; Linder, S. Proteasome deubiquitinases as novel targets for cancer therapy. Int. J. Biochem. Cell. Biol., 2012, 44, 1729-1738.
187. Elliott, P. J.; Pien, C. S.; McCormack, T. A.; Chapman, I. D.; Adams, J. Proteasome inhibition: A novel mechanism to combat asthma. J. Allergy Clin. Immunol., 1999, 104, 294-300.
188. Fisher, R. I.; Bernstein, S. H.; Kahl, B. S.; Djulbegovic, B.; Robertson, M. J.; de Vos, S.; Epner, E.; Krishnan, A.; Leonard, J. P.; Lonial, S.; Stadtmauer, E. A.; O'Connor, O. A.; Shi, H.; Boral, A. L.; Goy, A. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J. Clin. Oncol., 2006, 24, 4867-4874.
189. Schenkein, D. Proteasome inhibitors in the treatment of B-cell malignancies. Clin. Lymphoma, 2002, 3, 49-55.
190. Shah, S. A.; Potter, M. W.; McDade, T. P.; Ricciardi, R.; Perugini, R. A.; Elliott, P. J.; Adams, J.; Callery, M. P. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell. Biochem., 2001, 82, 110-122.
191. Scharf, C. The benevolence of black holes. Sci. Am., 2012, 307, 34-39.
192. Bean, J. F.; Vora, A.; Frontera, W. R. Benefits of exercise for community-dwelling older adults. Arch. Phys. Med. Rehabil., 2004, 85, S31-S42.
193. Heo, J.; Culp, B.; Yamada, N.; Won, Y. Promoting successful aging through competitive sports participation: insights from older adults. Qual. Health Res., 2013, 23, 105-113.
194. Packer, L.; Cadenas, E.; Davies, K. J. Free radicals and exercise: an introduction. Free Radic. Biol. Med., 2008, 44, 123-125.
195. Sachdev, S.; Davies, K. J. Production.; detection, and adaptive responses to free radicals in exercise. Free Radic. Biol. Med., 2008, 44, 215-223.
196. Powers, S. K.; Duarte, J.; Kavazis, A. N.; Talbert, E. E. Reactive oxygen species are signalling molecules for skeletal muscle adaptation. Exp. Physiol., 2010, 95, 1-9.
197. Powers, S. K.; Nelson, W. B.; Hudson, M. B. Exercise-induced oxidative stress in humans: cause and consequences. Free Radic. Biol. Med., 2011, 51, 942-950.
198. Nakatani, K.; Komatsu, M.; Kato, T.; Yamanaka, T.; Takekura, H.; Wagatsuma, A.; Aoyama, K.; Xu, B.; Hirano, T.; Kasai, H.; Ando, S.; Takeuchi, T. Habitual exercise induced resistance to oxidative stress. Free Radic. Res., 2005, 39, 905-911.
199. Kang, C.; O'Moore, K. M.; Dickman, J. R.; Ji, L. L. Exercise activation of muscle peroxisome proliferator-activated receptor-gamma coactivator-1alpha signaling is redox sensitive. Free Radic. Biol. Med., 2009, 47, 1394-1400.
200. George, L.; Lokhandwala, M. F.; Asghar, M. Exercise activates redox-sensitive transcription factors and restores renal D1 receptor function in old rats. Am. J. Physiol. Renal Physiol., 2009, 297, F1174-F1180.
201. Little JP.; Safdar A.; Cermak N.; Tarnopolsky MA.; Gibala MJ. Acute endurance exercise increases the nuclear abundance of PGC-1alpha in trained human skeletal muscle. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2010, 298, R912-R917.
202. Ljubicic, V.; Joseph, A. M.; Saleem, A.; Uguccioni, G.; Collu-Marchese, M.; Lai, R. Y.; Nguyen, L. M.; Hood, D. A. Transcriptional and post-transcriptional regulation of mitochondrial biogenesis in skeletal muscle: effects of exercise and aging. Biochim. Biophys. Acta., 2010, 1800, 223-234.
203. Muthusamy, V. R.; Kannan, S.; Sadhaasivam, K.; Gounder, S. S.; Davidson, C. J.; Boeheme, C.; Hoidal, J. R.; Wang, L.; Rajasekaran, N. S. Acute exercise stress activates Nrf2/ARE signaling and promotes antioxidant mechanisms in the myocardium. Free Radic. Biol. Med., 2012, 52, 366-376.
204. Bocci, V. In: Ozone. A new medical drug; Springer; Dordrecht, Netherlands, 2011; pp. 133-145.
205. Nakao, A.; Sugimoto, R.; Billiar, T. R.; McCurry, K. R. Therapeutic antioxidant medical gas. J. Clin. Biochem. Nutr., 2009, 44, 1-13.
206. Knowles, R. G.; Moncada, S. Nitric oxide as a signal in blood vessels. Trends Biochem. Sci., 1992, 17, 399-402.
207. Calvert, J. W.; Jha, S.; Gundewar, S.; Elrod, J. W.; Ramachandran, A.; Pattillo, C. B.; Kevil, C. G.; Lefer, D. J. Hydrogen sulfide mediates cardioprotection through Nrf2 signaling. Circ. Res., 2009, 105, 365-374.
208. Calvert, J. W.; Coetzee, W. A.; Lefer, D. J. Novel insights into hydrogen sulfide - mediated cytoprotection. Antioxid. Redox. Signal., 2010, 12, 1203-1217.
209. 2-induced oxidative damage-implications for the treatment of osteoporosis. Free Radic. Biol. Med., 2011, 50, 1314-1323.
210. Nakao, A.; Faleo, G.; Nalesnik, M. A.; Seda-Neto, J.; Kohmoto, J.; Murase, N. Low-dose carbon monoxide inhibits progressive chronic allograft nephropathy and restores renal allograft function. Am. J. Physiol. Renal Physiol., 2009, 297, F19-26.
211. Pannen, B. H.; Köhler, N.; Hole, B.; Bauer, M.; Clemens, M. G.; Geiger, K. K. Protective role of endogenous carbon monoxide in hepatic microcirculatory dysfunction after hemorrhagic shock in rats. J. Clin. Invest., 1998, 102, 1220-1208.
212. Ryter, S. W.; Otterbein, L. E.; Morse, D.; Choi, A. M. Heme oxygenase/carbon monoxide signaling pathways: regulation and functional significance. Mol. Cell. Biochem., 2002, 234-235, 249-263.
213. Verma, A.; Hirsch, D. J.; Glatt, C. E.; Ronnett, G. V.; Snyder, S. H. Carbon monoxide: a putative neural messenger. Science, 1993, 259, 381-384.
214. George, J. F.; Agarwal, A. Hydrogen: another gas with therapeutic potential. Kidney Int., 2010, 77, 85-87.
215. Ohsawa, I.; Ishikawa, M.; Takahashi, K.; Watanabe, M.; Nishimaki, K.; Yamagata, K.; Katsura, K.; Katayama, Y.; Asoh, S.; Ohta, S. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat. Med., 2007, 13, 688-694.
216. Ohta, S.; Nakao, A.; Ohno, K. The 2011 Medical Molecular Hydrogen Symposium: An inaugural symposium of the journal Medical Gas Research. Med. Gas. Res., 2011, 1, 10.
217. Bocci, V. Is it true that ozone is always toxic? The end of a dogma. Toxicol. Appl. Pharmacol., 2006, 216, 493-504.
218. Bocci, V.; Borrelli, E.; Travagli, V.; Zanardi, I. The ozone paradox: ozone is a strong oxidant as well as a medical drug. Med. Res. Rev., 2009, 29, 646-682.
219. Timbrell, J. A. The Poison Paradox: Chemicals as Friends and Foes; Oxford University Press: Oxford, New York, 2005.
220. Bocci, V. A. Tropospheric ozone toxicity vs. usefulness of ozone therapy. Arch. Med. Res., 2007, 38, 265-267.
221. Bell, M. L.; Dominici, F.; Samet, J. M. A meta-analysis of timeseries studies of ozone and mortality with comparison to the national morbidity, mortality, and air pollution study. Epidemiology, 2005, 16, 436-445.
222. Bhalla, D. K.; Gupta, S. K. Lung injury, inflammation, and inflammatory stimuli in rats exposed to ozone. J. Toxicol. Environ. Health A., 2000, 59, 211-228.
223. Jerrett, M.; Burnett, R. T.; Pope, C. A. 3rd.; Ito, K.; Thurston, G.; Krewski, D.; Shi, Y.; Calle, E.; Thun, M. Long-term ozone exposure and mortality. N. Engl. J. Med., 2009, 360, 1085-1095.
224. Mustafa, M. G. Biochemical basis of ozone toxicity. Free Radic. Biol. Med., 1990, 9, 245-265.
225. Ruidavets, J. B.; Cournot, M.; Cassadou, S.; Giroux, M.; Meybeck, M.; Ferrières, J. Ozone air pollution is associated with acute myocardial infarction. Circulation, 2005, 111, 563-569.
226. Valacchi, G.; Weber, S. U.; Luu, C.; Cross, C. E.; Packer, L. Ozone potentiates vitamin E depletion by ultraviolet radiation in the murine stratum corneum. FEBS Lett., 2000, 466, 165-168.
227. Valacchi, G.; Pagnin, E.; Okamoto, T.; Corbacho, A. M.; Olano, E.; Davis, P. A.; van der Vliet, A.; Packer, L.; Cross, C. E. Induction of stress proteins and MMP-9 by 0.8 ppm of ozone in murine skin. Biochem. Biophys. Res. Commun., 2003, 305, 741-746.
228. Bastacky, J.; Lee, C. Y.; Goerke, J.; Koushafar, H.; Yager, D.; Kenaga, L.; Speed, T. P.; Chen, Y.; Clements, J. A. Alveolar lining layer is thin and continuous: low-temperature scanning electron microscopy of rat lung. J. Appl. Physiol., 1995, 79, 1615-1628.
229. Bocci, V. A. Scientific and medical aspects of ozone therapy. State of the art. Arch. Med. Res., 2006, 37, 425-435.
230. Bocci, V.; Aldinucci, C. Biochemical modifications induced in human blood by oxygenation-ozonation. J. Biochem. Mol. Toxicol., 2006, 20, 133-138.
231. May. J. M.; Cobb, C. E.; Mendiratta, S.; Hill, K. E.; Burk, R. F. Reduction of the ascorbyl free radical to ascorbate by thioredoxin reductase. J. Biol. Chem., 1998, 273, 23039-23045.
232. Mendiratta, S.; Qu, Z. C.; May, J. M. Erythrocyte ascorbate recycling: antioxidant effects in blood. Free Radic. Biol. Med., 1998, 24, 789-797.
233. 2 gradients across biomembranes. FEBS Lett., 2000, 475, 121-126.
234. Stone, J. R.; Yang, S. Hydrogen peroxide: a signaling messenger. Antioxid. Redox. Signal., 2006, 8, 243-270.
235. Bocci, V. Oxygen-Ozone Therapy: A Critical Evaluation.; The Netherlands, Kluwer Academic Publisher: Dordrecht, 2002.
236. Baeuerle, P. A.; Henkel, T. Function and activation of NF-kappa B in the immune system. Annu. Rev. Immunol., 1994, 12, 141-179.
237. Bocci, V.; Paulesu, L. Studies on the biological effects of ozone 1. Induction of interferon gamma on human leucocytes. Haematologica, 1990, 75, 510-515.
238. Bocci, V.; Luzzi, E.; Corradeschi, F.; Paulesu, L.; Di Stefano, A. Studies on the biological effects of ozone: 3. An attempt to define conditions for optimal induction of cytokines. Lymphokine Cytokine Res., 1993, 12, 121-126.
239. Bocci, V.; Valacchi, G.; Corradeschi, F.; Fanetti, G. Studies on the biological effects of ozone: 8. Effects on the total antioxidant status and on interleukin-8 production. Mediators Inflamm., 1998, 7, 313-317.
240. Bocci, V.; Valacchi, G.; Rossi, R.; Giustarini, D.; Paccagnini, E.; Pucci, A. M.; Di Simplicio, P. Studies on the biological effects of ozone: 9. Effects of ozone on human platelets. Platelets, 1999, 10, 110-116.
241. Valacchi, G.; Bocci, V. Studies on the biological effects of ozone: 10. Release of factors from ozonated human platelets. Mediators Inflamm., 1999, 8, 205-209.
242. Awasthi, Y. C.; Yang, Y.; Tiwari, N. K.; Patrick, B.; Sharma, A.; Li, J.; Awasthi, S. Regulation of 4-hydroxynonenal-mediated signaling by glutathione S-transferases. Free Radic. Biol. Med., 2004, 37, 607-619.
243. Petersen, D. R.; Doorn, J. A. Reactions of 4-hydroxynonenal with proteins and cellular targets. Free Radic. Biol. Med., 2004, 37, 937-945.
244. Siems, W.; Grune, T. Intracellular metabolism of 4-hydroxynonenal. Mol. Aspects Med., 2003, 24, 167-175.
245. Alary, J.; Bravais, F.; Cravedi, J. P.; Debrauwer, L.; Rao, D.; Bories, G. Mercapturic acid conjugates as urinary end metabolites of the lipid peroxidation product 4-hydroxy-2-nonenal in the rat. Chem. Res. Toxicol., 1995, 8, 34-39.
246. Laurent, A.; Alary, J.; Debrauwer, L.; Cravedi, J. P. Analysis in the rat of 4-hydroxynonenal metabolites excreted in bile: evidence of enterohepatic circulation of these byproducts of lipid peroxidation. Chem. Res. Toxicol., 1999, 12, 887-894.
247. Dianzani, M. U. 4-Hydroxynonenal and cell signalling. Free Radic. Res., 1998, 28, 553-560.
248. Bocci, V.; Borrelli, E.; Valacchi, G.; Luzzi, E. Quasi-total-body exposure to an oxygen-ozone mixture in a sauna cabin. Eur. J. Appl. Physiol. Occup. Physiol., 1999, 80, 549-554.
249. Bocci, V.; Zanardi, I.; Michaeli, D.; Travagli, V. Mechanisms of Action and Chemical-Biological Interactions Between Ozone and Body Compartments: A Critical Appraisal of the Different Administration Routes. Curr. Drug Therapy, 2009, 4, 159-173.
250. Bocci, V.; Zanardi, I.; Travagli, V. Potentiality of oxygenozonetherapy to improve the health of aging people. Curr. Aging Sci., 2010, 3, 177-187.
251. Bocci, V.; Zanardi, I.; Travagli, V. Ozone: a new therapeutic agent in vascular diseases. Am. J. Cardiovasc. Drugs, 2011, 11, 73-82.
252. Bocci. V.; Zanardi. I.; Borrelli. E.; Travagli. V. Reliable and effective oxygen-ozone therapy at a crossroads with ozonated saline infusion and ozone rectal insufflation. J. Pharm. Pharmacol., 2012, 64, 482-489.
253. Sagai, M.; Bocci, V. Mechanisms of Action Involved in Ozone Therapy: Is healing induced via a mild oxidative stress? Med. Gas. Res., 2011, 1, 29.
254. Ajamieh, H.; Merino, N.; Candelario-Jalil, E.; Menéndez, S.; Martinez-Sanchez, G.; Re, L.; Giuliani, A.; Leon, O. S. Similar protective effect of ischaemic and ozone oxidative preconditionings in liver ischaemia/reperfusion injury. Pharmacol. Res., 2002, 45, 333-339.
255. Ajamieh, H. H.; Berlanga, J.; Merino, N.; Sánchez, G. M.; Carmona, A. M.; Cepero, S. M.; Giuliani A.; Re L.; León OS. Role of protein synthesis in the protection conferred by ozone-oxidativepreconditioning in hepatic ischaemia/reperfusion. Transpl. Int., 2005, 18, 604-612.
256. Barber, E.; Menéndez, S.; León, O. S.; Barber, M. O.; Merino, N.; Calunga, J. L.; Cruz, E.; Bocci, V. Prevention of renal injury after induction of ozone tolerance in rats submitted to warm ischaemia. Mediators Inflamm., 1999, 8, 37-41.
257. Bocci, V.; Aldinucci, C.; Mosci, F.; Carraro, F.; Valacchi, G. Ozonation of human blood induces a remarkable upregulation of heme oxygenase-1 and heat stress protein-70. Mediators Inflamm., 2007, 2007, 26785.
258. Candelario-Jalil, E.; Mohammed-Al-Dalain, S.; Fernández, O. S.; Menéndez, S.; Pérez-Davison, G.; Merino, N.; Sam, S.; Ajamieh, H. H. Oxidative preconditioning affords protection against carbon tetrachloride-induced glycogen depletion and oxidative stress in rats. J. Appl. Toxicol., 2001, 21, 297-301.
259. Chen, H.; Xing, B.; Liu, X.; Zhan, B.; Zhou, J.; Zhu, H.; Chen, Z. Ozone oxidative preconditioning protects the rat kidney from reperfusion injury: the role of nitric oxide. J. Surg. Res., 2008, 149, 287-295.
260. Di Filippo, C.; Marfella, R.; Capodanno, P.; Ferraraccio, F.; Coppola, L.; Luongo, M.; Mascolo, L.; Luongo, C.; Capuano, A.; Rossi, F.; D'Amico, M. Acute oxygen-ozone administration to rats protects the heart from ischemia reperfusion infarct. Inflamm. Res., 2008, 57, 445-449.
261. El-Sawalhi, M. M.; Shaheen, A. Modulation of age-related changes in oxidative stress markers and energy status in the rat heart and hippocampus: A significant role for ozone therapy. Cell Biochem. Funct., In press; 2012.
262. Frosini, M.; Contartese, A.; Zanardi, I.; Travagli, V.; Bocci, V. Selective ozone concentrations may reduce the ischemic damage after a stroke. Free Radic. Res., 2012, 46, 612-618.
263. Larini, A.; Bianchi, L.; Bocci, V. The ozone tolerance: I) Enhancement of antioxidant enzymes is ozone dose-dependent in Jurkat cells. Free Radic. Res., 2003, 37, 1163-1168.
264. Biedunkiewicz, B.; Tylicki, L.; Nieweglowski, T.; Burakowski, S.; Rutkowski, B. Clinical efficacy of ozonated autohemotherapy in hemodialyzed patients with intermittent claudication: an oxygencontrolled study. Int. J. Artif. Organs, 2004, 27, 29-34.
265. Bocci, V.; Zanardi, I.; Huijberts, M. S.; Travagli, V. Diabetes and chronic oxidative stress. A perspective based on the possible usefulness of ozone therapy. Diabetes Metab. Syndr., 2011, 5, 45-49.
266. Borrelli, E, Diadori, A, Zalaffi, A, Bocci, V, Effects of major ozonated autohemotherapy in the treatment of dry age macular degeneration: a randomized controlled clinical study. Int. J. Ophthalmol., 2012, 5, 708-713.
267. de Monte A.; van der Zee H.; Bocci V. Major ozonated autohemotherapy in chronic limb ischemia with ulcerations. J. Altern. Complement. Med., 2005, 11, 363-367.
268. Di Paolo, N.; Bocci, V.; Cappelletti, F.; Petrini, G.; Gaggiotti, E. Necrotizing fasciitis successfully treated with extracorporeal blood oxygenation and ozonization (EBOO). Int. J. Artif. Organs, 2002, 25, 1194-1198.
269. Di Paolo, N.; Bocci, V.; Salvo, DP.; Palasciano, G.; Biagioli, M.; Meini, S.; Galli, F.; Ciari, I.; Maccari, F.; Cappelletti, F.; Di Paolo, M.; Gaggiotti, E. Extracorporeal blood oxygenation and ozonation (EBOO): a controlled trial in patients with peripheral artery disease. Int. J. Artif. Organs, 2005, 28, 1039-1050.
270. Giunta, R.; Coppola, A.; Luongo, C.; Sammartino, A.; Guastafierro, S.; Grassia, A.; Giunta, L.; Mascolo, L.; Tirelli, A.; Coppola, L. Ozonized autohemotransfusion improbe hemorheological parameters and oxygen delivery to tissues in patients with peripheral occlusive arterial disease. Ann. Hematol., 2001, 80, 745-748.
271. Hernández, F.; Menéndez, S.; Wong, R. Decrease of blood cholesterol and stimulation of antioxidative response in cardiopathy patients treated with endovenous ozone therapy. Free Radic. Biol. Med., 1995, 19, 115-119.
272. Mattassi, R.; D'Angelo, F.; Bisetti, P.; Colombo, R.; Vaghi, M. Terapia con ozono per via parenterale nelle arteriopatie obliteranti periferiche: meccanismo biochimico e risultati clinici. Il Giornale di Chirurgia, 1987, VIII, 109-111.
273. Rokitansky, O.; Rokitansky, A.; Steiner, I.; Trubel, W.; Viebahn, R.; Washüttl, J. Die Ozontherapie bei peripheren, arteriellen Durchblutungs störungen; klinik, biochemische und blutgasanalytische Untersuchungen. Wasser IOA, Ozon-Weltkongress, Berlin, Germany, 1981, 53-75.
274. Tylicki, L.; Nieweglowski, T.; Biedunkiewicz, B.; Chamienia, A.; Debska-Slizien, A.; Aleksandrowicz, E.; Lysiak-Szydlowska, W.; Rutkowski, B. The influence of ozonated autohemotherapy on oxidative stress in hemodialyzed patients with atherosclerotic ischemia of lower limbs. Int. J. Artif. Organs, 2003, 26, 297-303.
275. Jacobs, M. T. Untersuchung uber zwishenfalle und typische komplikationen in der ozon-sauerstoff-therapie. Ozonachrichten, 1982, 1-5.
276. Travagli, V.; Zanardi, I.; Silvietti, A.; Bocci, V. A physicochemical investigation on the effects of ozone on blood. Int. J. Biol. Macromol., 2007, 41, 504-511.
277. Calkins, M. J.; Johnson, D. A.; Townsend, J. A.; Vargas, M. R.; Dowell, J. A.; Williamson, T. P.; Kraft, A. D.; Lee, J. M.; Li, J.; Johnson, J. A. The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid. Redox. Signal., 2009, 11, 497-508.
278. Jung, K. A.; Kwak, M. K. The Nrf2 system as a potential target for the development of indirect antioxidants. Molecules, 2010, 15, 7266-7291.
279. Kensler, T. W.; Wakabayashi, N.; Biswal, S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 89-116.
280. Kwak, M. K.; Kensler, T. W. Targeting NRF2 signaling for cancer chemoprevention. Toxicol. Appl. Pharmacol., 2010, 244, 66-76.
281. Li, W.; Kong, A. N. Molecular mechanisms of Nrf2-mediated antioxidant response. Mol. Carcinog., 2009, 48, 91-104.
282. Li, W.; Khor, T. O.; Xu, C.; Shen, G.; Jeong, W. S.; Yu, S.; Kong, A. N. Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis. Biochem. Pharmacol., 2008, 76, 1485-1489.
283. Motohashi, H.; Yamamoto, M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol. Med., 2004, 10, 549-557.
284. Taguchi, K.; Motohashi, H.; Yamamoto, M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells., 2011, 16, 123-140.
285. Talalay, P.; Fahey, J. W.; Holtzclaw, W. D.; Prestera, T.; Zhang, Y. Chemoprotection against cancer by phase 2 enzyme induction. Toxicol. Lett., 1995, 82-83, 173-179.
286. Zhang, D. D. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab. Rev., 2006, 38, 769-789.
287. Pecorelli, A.; Bocci, V.; Acquaviva, A.; Belmonte, G.; Gardi, C.; Virgili, F.; Ciccoli, L.; Valacchi, G. Nrf2 activation is involved in ozonated human serum upregulation of HO1 in endothelial cells. Toxicol. Appl. Pharmacol., 2013, 267, 30-40.
288. Yang, Y. C.; Lii, C. K.; Lin, A. H.; Yeh, Y. W.; Yao, H. T.; Li, C. C.; Liu, K. L.; Chen, H. W. Induction of glutathione synthesis and heme oxygenase 1 by the flavonoids butein and phloretin is mediated through the ERK/Nrf2 pathway and protects against oxidative stress. Free Radic. Biol. Med., 2011, 51, 2073-2081.
289. Kansanen, E.; Bonacci, G.; Schopfer, F. J.; Kuosmanen, S. M.; Tong, K. I.; Leinonen, H.; Woodcock, S. R.; Yamamoto, M.; Carlberg, C.; Ylä-Herttuala, S.; Freeman, B. A.; Levonen, A. L. Electrophilic nitro-fatty acids activate NRF2 by a KEAP1 cysteine 151-independent mechanism. J. Biol. Chem., 2011, 286, 14019-14027.
290. Um, H. C.; Jang, J. H.; Kim, D. H.; Lee, C.; Surh, Y. J. Nitric oxide activates Nrf2 through S-nitrosylation of Keap1 in PC12 cells. Nitric Oxide., 2011, 25, 161-168.
291. Brewer, A. C.; Murray, T. V.; Arno, M.; Zhang, M.; Anilkumar, N. P.; Mann, G. E.; Shah, A. M. Nox4 regulates Nrf2 and glutathione redox in cardiomyocytes in vivo. Free Radic. Biol. Med., 2011, 51, 205-215.
292. He, M.; Siow, R. C.; Sugden, D.; Gao, L.; Cheng, X.; Mann, G. E. Induction of HO-1 and redox signaling in endothelial cells by advanced glycation end products: a role for Nrf2 in vascular protection in diabetes. Nutr. Metab. Cardiovasc. Dis., 2011, 21, 277-285.
293. Miura, T.; Shinkai, Y.; Jiang, H. Y.; Iwamoto, N.; Sumi, D.; Taguchi, K.; Yamamoto, M.; Jinno, H.; Tanaka-Kagawa, T.; Cho, A. K.; Kumagai, Y. Initial response and cellular protection through the Keap1/Nrf2 system during the exposure of primary mouse hepatocytes to 1,2-naphthoquinone. Chem. Res. Toxicol., 2011, 24, 559-567.
294. Almazari, I.; Park, J. M.; Park, S. A.; Suh, J. Y.; Na, H. K.; Cha, Y. N.; Surh, Y. J. Guggulsterone induces heme oxygenase-1 expression through activation of Nrf2 in human mammary epithelial cells: PTEN as a putative target. Carcinogenesis, 2012, 33, 368-376.
295. Frizzell, N.; Thomas, S. A.; Carson, J. A.; Baynes, J. W. Mitochondrial stress causes increased succination of proteins in adipocytes in response to glucotoxicity. Biochem. J., 2012, 445, 247-254.
296. Ooi, A.; Wong, J. C.; Petillo, D.; Roossien, D.; Perrier-Trudova, V.; Whitten, D.; Min, B. W.; Tan, M. H.; Zhang, Z.; Yang, X. J.; Zhou, M.; Gardie, B.; Molinié, V.; Richard, S.; Tan, P. H.; The, B. T.; Furge, K. A. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell., 2011, 20, 511-523.
297. Yang, M.; Soga, T.; Pollard, P. J.; Adam, J. The emerging role of fumarate as an oncometabolite. Front. Oncol., 2012, 2, 85.
298. Speakman, J. R.; Mitchell, S. E. Caloric restriction. Mol. Aspects Med., 2011, 32, 159-221.
299. Muthusamy, V. R.; Kannan, S.; Sadhaasivam, K.; Gounder, S. S.; Davidson, C. J.; Boeheme, C.; Hoidal, J. R.; Wang, L.; Rajasekaran, N. S. Acute exercise stress activates Nrf2/ARE signaling and promotes antioxidant mechanisms in the myocardium. Free Radic. Biol. Med., 2012, 52, 366-376.
300. Patel, R.; Maru, G. Polymeric black tea polyphenols induce phase II enzymes via Nrf2 in mouse liver and lungs. Free Radic. Biol. Med., 2008, 44, 1897-1911.
301. Tanigawa, S.; Fujii, M.; Hou, D. X. Action of Nrf2 and Keap1 in ARE-mediated NQO1 expression by quercetin. Free Radic. Biol. Med., 2007, 42, 1690-1703.
302. Murakami, A.; Ohnishi, K. Target molecules of food phytochemicals: food science bound for the next dimension. Food Funct., 2012, 3, 462-476.
303. Seife, C. Is drug research trust worthy? Sci. Am., 2012, 307, 42-49.
304. Warnholtz, A.; Münzel, T. Why do antioxidants fail to provide clinical benefit? Curr. Control Trials Cardiovasc. Med., 2000, 1, 38-40.